Drugs /

autologous genetically-modified mage-a4 c1032 t cells

Back to Drugs List

Overview

NCI Definition [1]:
Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous genetically-modified MAGE-A4 C1032 T-cells bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.

Clinical Trials

View Clinical Trials for autologous genetically-modified mage-a4 c1032 t cells

Autologous genetically-modified mage-a4 c1032 t cells has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating autologous genetically-modified mage-a4 c1032 t cells, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).

HLA-A*02 Positive and MAGEA4 Expression are the most frequent biomarker inclusion criteria for autologous genetically-modified mage-a4 c1032 t cells clinical trials.

Myxoid liposarcoma, synovial sarcoma, and head and neck squamous cell carcinoma are the most common diseases being investigated in autologous genetically-modified mage-a4 c1032 t cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Autologous Genetically-Modified Mage-A4 C1032 T Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating autologous genetically-modified mage-a4 c1032 t cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous genetically-modified mage-a4 c1032 t lymphocytes, autologous genetically-modified melanoma antigen a4 t cells, spear t-cell adp-a2m4, mage-a4 spear t-cells, adp-a2m4, mage-a4-specific tcr gene-transduced c1032 t-lymphocytes, autologous tcr-transduced mage-a4 c1032 t cells, autologous mage-a4 c1032 tcr-modified t cells
Drug Target(s) [2]:
MAGEA4
NCIT ID [1]:
C138107

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.